Neogen Chemicals Ltd
Neogen Chemicals Ltd, incorporated in 1991, manufactures bromine and lithium-based organic and organo-metallic compounds, used in the pharmaceutical, agricultural chemicals, and engineering industries. [1]
- Market Cap ₹ 3,584 Cr.
- Current Price ₹ 1,359
- High / Low ₹ 1,859 / 1,149
- Stock P/E 108
- Book Value ₹ 189
- Dividend Yield 0.22 %
- ROCE 13.2 %
- ROE 10.8 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 35.4% CAGR over last 5 years
Cons
- Stock is trading at 7.21 times its book value
- Promoter holding has decreased over last quarter: -3.30%
- Company has a low return on equity of 13.4% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|
74 | 84 | 100 | 110 | 161 | 239 | 306 | 336 | 487 | 686 | 695 | |
62 | 71 | 86 | 90 | 132 | 196 | 248 | 272 | 401 | 575 | 588 | |
Operating Profit | 11 | 13 | 14 | 20 | 29 | 43 | 58 | 64 | 87 | 112 | 107 |
OPM % | 16% | 15% | 14% | 18% | 18% | 18% | 19% | 19% | 18% | 16% | 15% |
0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 5 | 7 | |
Interest | 5 | 5 | 5 | 8 | 10 | 12 | 12 | 14 | 19 | 29 | 42 |
Depreciation | 1 | 1 | 1 | 1 | 2 | 3 | 5 | 7 | 12 | 16 | 21 |
Profit before tax | 6 | 8 | 8 | 12 | 17 | 29 | 41 | 44 | 57 | 71 | 51 |
Tax % | 41% | 37% | 39% | 33% | 37% | 28% | 30% | 29% | 22% | 30% | |
4 | 5 | 5 | 8 | 11 | 21 | 29 | 31 | 45 | 50 | 33 | |
EPS in Rs | 8.09 | 11.31 | 2.59 | 3.84 | 5.49 | 10.43 | 12.28 | 13.43 | 17.90 | 20.04 | 13.23 |
Dividend Payout % | 25% | 18% | 17% | 0% | 18% | 14% | 16% | 17% | 15% | 15% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 34% |
3 Years: | 31% |
TTM: | 9% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 35% |
3 Years: | 20% |
TTM: | -36% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 16% |
1 Year: | -16% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 16% |
3 Years: | 13% |
Last Year: | 11% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 4 | 4 | 20 | 20 | 20 | 20 | 23 | 23 | 25 | 25 | 25 |
Reserves | 15 | 19 | 8 | 22 | 30 | 50 | 133 | 160 | 414 | 458 | 472 |
Preference Capital | 0 | 0 | 0 | 0 | 13 | 12 | 0 | 0 | 0 | 0 | |
25 | 24 | 26 | 69 | 69 | 108 | 137 | 222 | 229 | 370 | 479 | |
18 | 21 | 26 | 41 | 61 | 68 | 61 | 87 | 131 | 202 | 226 | |
Total Liabilities | 63 | 69 | 80 | 152 | 180 | 246 | 355 | 492 | 799 | 1,054 | 1,202 |
14 | 13 | 17 | 56 | 67 | 83 | 111 | 127 | 285 | 347 | 361 | |
CWIP | 0 | 0 | 1 | 1 | 1 | 0 | 3 | 115 | 11 | 36 | 101 |
Investments | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 82 | 77 | 37 |
49 | 55 | 62 | 94 | 112 | 163 | 241 | 250 | 422 | 594 | 703 | |
Total Assets | 63 | 69 | 80 | 152 | 180 | 246 | 355 | 492 | 799 | 1,054 | 1,202 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
9 | 9 | 0 | 12 | -4 | -35 | 84 | 1 | -30 | ||
-2 | -4 | -33 | -13 | -20 | -29 | -135 | -146 | -94 | ||
-6 | -4 | 33 | -0 | 24 | 63 | 51 | 188 | 100 | ||
Net Cash Flow | 1 | 0 | 1 | -1 | 0 | -1 | -0 | 44 | -25 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 82 | 78 | 58 | 107 | 94 | 93 | 90 | 85 | 82 | 94 |
Inventory Days | 173 | 178 | 190 | 228 | 192 | 188 | 257 | 211 | 258 | 275 |
Days Payable | 117 | 120 | 130 | 177 | 141 | 111 | 71 | 122 | 131 | 147 |
Cash Conversion Cycle | 138 | 136 | 117 | 158 | 145 | 169 | 276 | 174 | 209 | 223 |
Working Capital Days | 140 | 140 | 126 | 174 | 142 | 162 | 217 | 164 | 190 | 205 |
ROCE % | 27% | 26% | 23% | 23% | 26% | 22% | 17% | 14% | 13% |
Documents
Announcements
- Certificate Under Regulation 40 (9) Of SEBI (LODR) Regulation, 2015 ('SEBI Regulations') For The Financial Year Ended March 31, 2024. 11 Apr
- Compliance Certificate Pursuant To Regulation 7(3) Of SEBI (LODR) Regulations, 2015 1 Apr
- Closure of Trading Window 30 Mar
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 12 Mar
- Announcement under Regulation 30 (LODR)-Credit Rating 11 Mar
Annual reports
Concalls
-
Feb 2024TranscriptPPT
-
Feb 2024Transcript PPT REC
-
Feb 2024TranscriptNotesPPT
-
Nov 2023Transcript PPT
-
Sep 2023Transcript PPT REC
-
Aug 2023TranscriptNotesPPT
-
May 2023Transcript PPT REC
-
Apr 2023TranscriptNotesPPT
-
Mar 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Feb 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Nov 2020TranscriptNotesPPT
-
Aug 2020Transcript PPT
-
May 2020Transcript PPT
-
Feb 2020Transcript PPT
-
Nov 2019Transcript PPT
-
Aug 2019Transcript PPT
-
May 2019TranscriptNotesPPT
About
The company manufactures Bromine and Lithium-based chemical compounds, led by Indian technocrats. The company also manufactures Advance Intermediates in Pharma / Agro / Flavours and Fragrances. [1] As of Q1FY24, company has developed ~248 products from their own R&D.[2]Neogen is the largest importer of Lithium Carbonate & Lithium Hydroxide for last 3 decades – Strong Relationship with Global Leading Lithium Miners & Processors.[3]